Previous 10 | Next 10 |
Strongbridge Biopharma (NASDAQ: SBBP ) -16% after pricing $25M share offering. More news on: Strongbridge Biopharma plc, NuCana plc, Dave & Buster's Entertainment, Inc., Stocks on the move, , Read more ...
89bio (NASDAQ: ETNB ) has priced an upsized public offering of 3.3M (from 3M) common shares, including 3,025,000 shares offered by the company and 275,000 by a selling stockholder, at $28.00/share, for expected gross proceeds of ~$84.7M. More news on: 89bio, Inc., Healthcare stock...
Gainers: Arrowhead Pharmaceuticals (NASDAQ: ARWR ) +47% . More news on: Arrowhead Pharmaceuticals, Inc., Eastman Kodak Company, Myomo, Inc., Stocks on the move, , Read more ...
Gainers: Novus Therapeutics (NASDAQ: NVUS ) +162% . More news on: Novus Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Stocks on the move, , Read more ...
89bio ( ETNB +6.3% ) commenced an underwritten public offering of 3M shares including 2.7M shares offered by the company and 300K shares offered by certain of the company’s stockholders. More news on: 89bio, Inc., Healthcare stocks news, Read more ...
89bio (NASDAQ: ETNB ) announces positive results from a Phase 1b/2a clinical trial evaluating lead candidate BIO89-100 in patients with nonalcoholic steatohepatitis (NASH). More news on: 89bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and tolerability profile Strong efficacy profile with every two-week dosing Stat...
SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, Septemb...
Quick Take Metacrine ( MTCR ) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for NASH conditions. MTCR is entering Phase 2 trials and will have significant capital ...
SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of a Pha...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...